Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
- On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023
- Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection points
BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended March 31, 2023.
“During the first quarter, we made significant progress with our Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors. This trial continues to attract top oncologists and academic centers, and patient enrollment is on track for us to have initial data to share in the second half of the year. We remain excited about the prospect of bringing a potential therapeutic option to a range of indications driven by MYC, one of the most frequently altered families of oncogenes,” said Markus Warmuth, M.D., CEO of Monte Rosa. “Furthermore, we expect to declare a development candidate in our VAV1 program in the second quarter. This milestone will mark a significant advancement in our pipeline of MGD-based medicines in the field of immunology and inflammation. We believe the underlying biology and our preclinical data support the potential of our VAV1-directed MGD to provide clinical benefit in multiple autoimmune diseases. Our continued progress with our pipeline speaks to the power of our QuEEN discovery engine and our position as a leading molecular glue degrader company. Backed by a strong balance sheet and a sharp focus on developing impactful medicines, we look forward to continuing to further the development of our molecular glue therapeutics.”
FIRST QUARTER 2023 AND RECENT HIGHLIGHTS
- Presented preclinical data highlighting the preferential activity of MRT-2359, an orally bioavailable GSPT1-directed MGD, in MYC-driven tumor cells at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL
- Appointed Jan Skvarka, Ph.D., MBA, an accomplished biopharmaceutical executive with extensive operational, strategic, and financial expertise to the Company’s Board of Directors
UPCOMING MILESTONES
- On track to announce initial clinical data, including pharmacokinetic (PK), pharmacodynamic (PD), safety, and available initial efficacy data from the Phase 1 part of the ongoing Phase 1/2 clinical trial evaluating MRT-2359 in MYC-driven tumors, including non-small cell lung cancer, small cell lung cancer, and other MYC-driven tumors, in the second half of 2023
- On track to advance multiple preclinical programs to development candidates in immunology, inflammation, and oncology, including declaring a VAV1 development candidate in the second quarter of 2023
FIRST QUARTER 2023 FINANCIAL RESULTS
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2023 were
General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2023 were
Net Loss: Net loss for the first quarter of 2023 was
Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023, were
About MRT-2359
MRT-2359 is a potent, selective and orally bioavailable molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein. The MYC transcription factors (c‑MYC, L-MYC and N-MYC) are well-established drivers of human cancers that maintain high levels of protein translation, which is critical for uncontrolled cell proliferation and tumor growth. Preclinical studies have shown that this addiction to MYC-induced protein translation creates a dependency on GSPT1. By inducing degradation of GSPT1, MRT-2359 exploits this vulnerability, disrupting the protein synthesis machinery, leading to anti-tumor activity in MYC-driven tumors.
About VAV1
VAV1, a Rho-family guanine nucleotide exchange factor, is a key signaling protein downstream of both the T and B cell receptors, whose expression is restricted to blood and immune cells, including T and B cells. Preclinical studies have shown that targeted degradation of VAV1 protein via an MGD modulates both T- and B-cell receptor-mediated activity in vitro and in vivo, as displayed by a significant decrease in cytokine secretion, as well as activity in preclinical models of immune diseases. VAV1-directed MGDs have the potential to provide therapeutic benefits in multiple autoimmune indications, such as multiple sclerosis, rheumatoid arthritis, and dermatological disorders.
About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing novel molecular glue degrader (MGD) medicines for patients living with serious diseases such as oncology, autoimmune and inflammatory diseases. The Company’s lead program, MRT-2359, is being developed in a Phase 1/2 study in MYC-driven tumors, including non-small cell lung cancer and small-cell lung cancer. MGDs are small molecule protein degraders designed to employ the body’s natural mechanisms to eliminate therapeutically relevant proteins selectively. The Company’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform enables it to rapidly identify protein targets and design highly selective degraders by combining diverse libraries of proprietary MGDs with in-house proteomics, structural biology, A.I./machine learning, and computational chemistry capabilities. For more information, visit www.monterosatx.com
Forward-Looking Statements
This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, statements about our product development activities, our ongoing clinical development of our GSPT1 degrader referred to as MRT-2359, including our expectations for the nature, significance, and timing for our disclosure of any initial data from our Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors, statements about the advancement of our preclinical programs, pipeline and the various products therein, including the ongoing development of our VAV1 directed molecular glue degrader program in the second quarter, our expectations regarding the potential clinical benefit for this program and our expectations of timings for the program, statements around the advancement and application of our pipeline and platform, and statements concerning our expectations regarding our ability to nominate and the timing of our nominations of additional targets, product candidates, and development candidates, as well as our expectations of success for our programs and the strength of our financial position, among others. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on March 16, 2023, and any subsequent filings, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research.
| Consolidated Balance Sheets | ||||||||
| (in thousands, except share amounts) | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 51,847 | $ | 54,912 | ||||
| Marketable securities | 179,887 | 207,914 | ||||||
| Other receivables | 2,170 | 7,656 | ||||||
| Prepaid expenses and other current assets | 5,692 | 4,444 | ||||||
| Current restricted cash | 960 | 960 | ||||||
| Total current assets | 240,556 | 275,886 | ||||||
| Property and equipment, net | 33,266 | 27,075 | ||||||
| Operating lease right-of-use assets | 30,534 | 34,832 | ||||||
| Restricted cash, net of current | 4,321 | 4,318 | ||||||
| Other long-term assets | 351 | 278 | ||||||
| Total assets | $ | 309,028 | $ | 342,389 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,382 | $ | 7,862 | ||||
| Accrued expenses and other current liabilities | 10,243 | 14,580 | ||||||
| Current portion of operating lease liability | 2,890 | 3,127 | ||||||
| Total current liabilities | 20,515 | 25,569 | ||||||
| Defined benefit plan liability | 1,512 | 1,533 | ||||||
| Operating lease liability | 43,275 | 43,874 | ||||||
| Total liabilities | 65,302 | 70,976 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, | 5 | 5 | ||||||
| Additional paid-in capital | 507,688 | 503,696 | ||||||
| Accumulated other comprehensive loss | (1,393 | ) | (1,752 | ) | ||||
| Accumulated deficit | (262,574 | ) | (230,536 | ) | ||||
| Total stockholders’ equity | 243,726 | 271,413 | ||||||
| Total liabilities and stockholders’ equity | $ | 309,028 | $ | 342,389 | ||||
| Consolidated Statement of Operations and Comprehensive Loss | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| (unaudited) | ||||||||
| Three months ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 26,755 | $ | 17,915 | ||||
| General and administrative | 7,504 | 6,387 | ||||||
| Total operating expenses | 34,259 | 24,302 | ||||||
| Loss from operations | (34,259 | ) | (24,302 | ) | ||||
| Other income (expense): | ||||||||
| Interest income, net | 2,437 | 149 | ||||||
| Foreign currency exchange (loss) gain, net | (85 | ) | 96 | |||||
| Gain on disposal of fixed assets | — | 125 | ||||||
| Loss on sale of marketable securities | (131 | ) | — | |||||
| Total other income | 2,221 | 370 | ||||||
| Net loss | $ | (32,038 | ) | $ | (23,932 | ) | ||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (0.65 | ) | $ | (0.51 | ) | ||
| Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted | 49,347,473 | 46,595,782 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (32,038 | ) | $ | (23,932 | ) | ||
| Other comprehensive loss: | ||||||||
| Provision for pension benefit obligation | 14 | 34 | ||||||
| Unrealized gain (loss) on available-for-sale securities | 345 | (146 | ) | |||||
| Comprehensive loss | $ | (31,679 | ) | $ | (24,044 | ) | ||
